Judges



The Sternfels Prize has assembled an elite group of judges with substantial medical, pharmacological, and research experience. The panel will review finalist submissions on a blinded basis and select a winner that best meets the competition’s criteria.


David J. Greenblatt, MD, FCP

Dan M. Roden, MD, PhD

Issam Zineh, PharmD, MPH

The Louis Lasagna, MD, Endowed Professor of Integrative Physiology & Pathology
Sam L. Clark, MD, PhD Endowed Professor of Medicine, Pharmacology, and Biomedical Informatics
Adjunct Professor in the College of Pharmacy
Tufts University
Vanderbilt University School of Medicine
University of North Carolina and Florida

2019 Judging Session


From left to right: Dan Roden, Issam Zineh, David Greenblatt

2018 Judging Session


From left to right: Dan Roden, David Greenblatt, Wayne (Nick) Nicholson, and Larry Lesko



Professor David J. Greenblatt, MD, FCP

The Louis Lasagna, MD, Endowed Chair of Integrative Physiology & Pathology
Tufts University


Dan M. Roden, MD, PhD

Sam L. Clark, MD, PhD Endowed Professor of Medicine, Pharmacology, and Biomedical Informatics
Vanderbilt University School of Medicine


Issam Zineh, PharmD, MPH

Adjunct Professor in the Colleges of Pharmacy
University of North Carolina and Florida


2019 Judging Session


From left to right: Dan Roden, Issam Zineh, and David Greenblatt

2018 Judging Session


From left to right: Dan Roden, David Greenblatt, Wayne (Nick) Nicholson, and Larry Lesko


In Memoriam

Darrell R. Abernethy MD, PhD

November 2, 1949 - November 18, 2017

Dr. Darrell Abernethy was a giant in his field. Most recently he served as Associate Director for Drug Safety at the FDA and held appointments at multiple academic institutions and the NIH over his career. Dr. Abernethy contributed heavily to the field of pharmacology and was a career long student and champion of drug safety. He was an ardent supporter of the Sternfels Prize from its inception. Despite being an expert’s expert himself, Dr. Abernethy strongly believed in the ‘wisdom of the crowd’ and that there were individuals from many professions who may be positioned to develop the idea that unlocks another major discovery in drug safety. His absence will be felt on the panel and in the field. To learn more about Dr. Abernethy and all the lives he touched, read his tribute from Dr. Greenblatt in the February edition of Clinical Pharmacology in Drug Development.